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Background
Since 2003, H5N1 avian influenza strains have become
endemic in many countries in Southeast Asia, including
Cambodia. In Cambodia alone there have been 26 out-
breaks in poultry flocks and 10 human cases with 9
deaths. We have analyzed the genome of a large panel
of H5N1 strains isolated from poultry and human
between 2004-2010. Several strains have molecular
alterations which are predicted to affect sensitivity to
neuraminidase inhibitors (NAI), the primary drugs of
choice in the treatment of H5N1 infections. In June
2009 the first H1N1 pandemic (H1N1pdm) viruses were
detected in Cambodia and have since been the main
influenza strains circulating during the epidemic season.
The aim of this study was primarily the surveillance of
oseltamivir and zanamivir drug resistance in Cambodian
H5N1 and H1N1pdm isolates.
Methods
A chemiluminescence-based in vitro assay of neuramini-
dase (NA) activity, which utilizes the artificial NA sub-
strate 1,2-dioxetane derivative of sialic acid (NA-STAR,
Applied Biosystems®), was used to determine the con-
centration of drug required to inhibit 50% of NA
enzyme activity (IC50).
Results
We have identified a small number of H5N1 outliers
with reduced susceptibility to NAIs and have further
characterized mutations predicted to affect drug resis-
tance using computer modeling, and recombinant
viruses containing these mutations generated by reverse
genetics. We have also investigated several previously
described resistance mutations in the context of the
Cambodian H5N1 virus using reverse genetics. We
found no evidence of NAI drug resistance in H1N1pdm
viruses in Cambodia.
Conclusion
We have monitored NAI sensitivity of H5N1 and
H1N1pdm viruses in Cambodia and in general have not
found NAI resistant viruses with classical resistance
mutations. However, we have identified naturally occur-
ring mutations in H5N1 viruses which reduce the sensi-
tivity to NAIs. The ongoing surveillance and
understanding of novel drug resistance mutations is of
great importance in the global efforts against influenza
disease and pandemics.
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